This unique international conference provides a platform for researchers and decision makers in biotechnology to present their latest findings and learn about all the important developments in biotechnology. Four Nobel Laureates and many world renowned experts will participate at the conference.

The conference will cover the translational nature of biotechnological research, with emphasis on both the basic science as well as its applications in industry and academia. Presentations will include latest researches, business development, strategic alliances, partnering trends, product opportunities, growth business models and strategies, licensing and pharmaceutical biotechnology (e.g. vaccines, CNS, cancer, antibodies), medical biotechnology, industrial biotechnology, bioprocess engineering, protein engineering, plant and environmental technologies, transgenic plant and crops, bioremediation, and microbial diversity research.

Throughout the course of the two day conference, you will have the opportunity to both network and hear leaders from the international academic and corporate biotechnology communities.

The conference is organized by Eureka Science with the support of the Higher Colleges of Technology, UAE, and it focuses on the interdisciplinary fields of biotechnology.

http://www.biotechworldcongress.com/

Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation

Meeting Summary

AIDS is incurable because cells latently infected with HIV resist antiviral therapy. Topical to the discussion of HIV eradication is the biology behind latent infection as well as models for the study of latency and pharmacological approaches to stimulate proviral gene expression. The Keystone Symposia meeting on Frontiers in HIV Pathogenesis, Therapy and Eradication will create an environment for free exchange of ideas and cutting edge results from a range of scientists in academia and industry in the fields of HIV pathogenesis, pharmacology, and eradication. Joint plenary sessions with the concurrent meeting on Cell Biology of Virus Entry, Replication and Pathogenesis will highlight common topics of interest including mechanisms of virus entry and inhibition, and will significantly enhance opportunities for interdisciplinary interactions. Leaders from HIV replication and drug resistance fields will critically examine the state of antiviral therapy, novel inhibitors, and important virus-host interactions. Speakers selected from submitted abstracts will fill-out workshops on pharmacological approaches and the cell biology of HIV infection.

http://www.keystonesymposia.org/meetings/viewMeetings.cfm?MeetingID=1166

AIDS is incurable because cells latently infected with HIV resist antiviral therapy. Topical to the discussion of HIV eradication is the biology behind latent infection as well as models for the study of latency and pharmacological approaches to stimulate proviral gene expression. The Keystone Symposia meeting on Frontiers in HIV Pathogenesis, Therapy and Eradication will create an environment for free exchange of ideas and cutting-edge results from a range of scientists in academia and industry in the fields of HIV pathogenesis, pharmacology and eradication.

http://www.keystonesymposia.org/Meetings/ViewMeetings.cfm?MeetingID=1166

This meeting series was initiated to promote discussion between specialists in quantitative and computational approaches in two areas in the field of HIV where these are particularly important.

1. Modeling of viral and cellular dynamics
2. Viral evolution and population genetics

Conference sessions will be organized to accommodate the best submitted talks. We welcome submissions on all topics on statistical, mathematical and computational approaches to analyzing HIV's dynamics and evolution.

Topics to be covered will include:

• HIV Dynamics Within the Host (transmission, disease progression, dual infection, recombination)
• HIV Dynamics Within the Population (epidemiology, phylodynamics, global diversity, paleovirology)
• New Computational Methods and Evolutionary Theory
• Evolution of the Host Response (host response to infection at the individual and at the population level
• Viral Dynamics and Evolution that Impact Vaccine Development and Drug Resistance

http://cme.ucsd.edu/hivdynamics/index.html

Despite major advances in the past 25 years, HIV infection remains a global threat with major scientific, societal and human challenges ahead. With an economic crisis able to undermine public investments, access to HIV prevention, HIV treatment and care are in jeopardy.
The ISHEID seeks to promote scientific excellence and to strengthen the global commitment against HIV/AIDS. It presents new scientific knowledge and offers many opportunities for structured dialogue on the major issues facing the global response against HIV/AIDS.

The 2012 programme will focus on current ‘hot topics’ in HIV research: understanding the mechanisms of HIV persistence and maintenance in reservoirs, trying to find a cure…, but also on socioeconomic and policy aspects. Different sessions will tackle ‘Human Rights & HIV/AIDS’, ‘Prevention of HIV Transmission’, ‘Access to Care’... Ultimately, the meeting will also address recent findings in the fields of viral hepatitis and emerging infectious diseases which need the same kind of global approach.

A variety of session types – from abstract-driven presentations to symposia, workshops and plenary lectures – will meet the needs of various participants. This human scale conference allows to meet international Key Opinion Leaders in a friendly atmosphere, to exchange ideas and to share experience. Consequently, the 2012 ISHEID will offer an exceptional opportunity for professional development and networking.

See you in Marseille in 2012!

Alain Lafeuillade
Symposium Chairman

http://www.isheid.com/en/home/welcome.html

Dear Colleagues,

The return of the International AIDS Conference to the United States in July 2012 represents a significant victory for public health and human rights. The selection of Washington, DC as the site for the XIX International AIDS Conference (AIDS 2012) is the result of years of dedicated advocacy to end the nation’s misguided entry restrictions on people living with HIV – restrictions that were based on fear, rather than science.
The biennial International AIDS Conference is the premier gathering for those working in the field of HIV, as well as policymakers, people living with HIV and others committed to ending the epidemic. It will be a tremendous opportunity for researchers from around the world to share the latest scientific advances in the field, learn from one another’s expertise, and develop strategies for advancing all facets of our collective efforts to treat and prevent HIV.
AIDS 2012 is expected to convene more than 25,000 delegates from nearly 200 countries, including more than 2,500 journalists. The conference will be held from 22 to 27 July 2012 at the Walter E. Washington Convention Center. The International AIDS Society, the world's leading independent association of HIV professionals, with 14,000 members in 190 countries, will organize AIDS 2012 in collaboration with our international and local partners.
We are gratified by the enthusiastic support expressed by our U.S. government and civil society partners for holding AIDS 2012 in Washington, DC. The world’s leading AIDS experts will gather for AIDS 2012 in a community deeply impacted by the epidemic, providing a tremendous opportunity for partnership and exchange that will further sow the seeds of solidarity among all of us dedicated to ending this scourge. The selection of Washington, DC, as the AIDS 2012 venue is also significant as it is home to key players in the global response to AIDS, including the Office of the U.S. Global AIDS Coordinator (which directs PEPFAR – President’s Emergency Plan for AIDS Relief), the National Institutes of Health and the World Bank.

AIDS 2012 will play a key role in shaping international responses to this devastating epidemic. As with all our conferences, we will work with partners to make sure that the conference has a deep and lasting impact in our host city and country. We look forward to partnering with the residents of Washington, DC, and with other groups across the U.S. to ensure the conference further strengthens the U.S. role in global AIDS initiatives, re-energizes the response to the U.S. domestic epidemic, and focuses attention on the particularly devastating impact HIV is having in Washington, DC, and in racial and ethnic minority communities across the U.S.

http://www.aids2012.org/

At this Congress, we are bringing together scientists from closely-related research communities by combining two conferences - the Biennial Conference of the International Association for Research on Epstein-Barr Virus (EBV) and Associated Diseases, and the Annual International Workshop on Kaposi's Sarcoma Associated Herpesvirus (KSHV) and Related Agents.

We hope that this joint conference will promote scientific interactions, fostering new collaborations and innovative research into tumor-associated herpesviruses.

We look forward to welcoming you to Philadelphia!

Congress Co-Chairs

Paul Lieberman, Ph.D., The Wistar Institute 
Erle Robertson, Ph.D., Perelman School of Medicine at the University of Pennsylvania
Yan Yuan, Ph.D., University of Pennsylvania School of Dental Medicine

http://www.penncancer.org/ICOHAD2012/